
HIV prevention drug lenacapavir accredited by FDA as twice-yearly injection
The U.S. Meals and Drug Administration has accredited the drug lenacapavir as a twice-yearly injection to stop HIV. The drug, referred to as Yeztugo from firm Gilead Sciences, was accredited Wednesday based mostly on information from scientific trials that confirmed 99.9% of contributors who acquired it remained HIV damaging. Daniel O’Day, Gilead’s chairman and chief…